Compare CLDX & PHIN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CLDX | PHIN |
|---|---|---|
| Founded | N/A | 2023 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.0B |
| IPO Year | 2008 | N/A |
| Metric | CLDX | PHIN |
|---|---|---|
| Price | $25.87 | $60.90 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 10 | 5 |
| Target Price | $44.10 | ★ $57.20 |
| AVG Volume (30 Days) | ★ 718.4K | 372.3K |
| Earning Date | 11-10-2025 | 10-28-2025 |
| Dividend Yield | N/A | ★ 1.81% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 2.18 |
| Revenue | $2,599,000.00 | ★ $3,427,000,000.00 |
| Revenue This Year | N/A | $2.70 |
| Revenue Next Year | $19.70 | $1.43 |
| P/E Ratio | ★ N/A | $27.35 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $14.40 | $36.25 |
| 52 Week High | $30.50 | $60.44 |
| Indicator | CLDX | PHIN |
|---|---|---|
| Relative Strength Index (RSI) | 44.96 | 76.70 |
| Support Level | $24.97 | $56.43 |
| Resistance Level | $28.79 | $58.82 |
| Average True Range (ATR) | 1.36 | 1.35 |
| MACD | -0.36 | 0.54 |
| Stochastic Oscillator | 16.46 | 92.90 |
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
Phinia Inc is engaged in the development, design, and manufacture of integrated components and systems that optimize performance, increase efficiency, and reduce emissions in combustion and hybrid propulsion for commercial vehicles, industrial applications, and light vehicles. Its product portfolio includes alternative fuel systems, fuel delivery modules, evaporative canisters, diesel fuel injection systems, electrical systems, hydrogen solutions, associated software, and others. The company's reportable segments are; the Fuel Systems segment, which derives key revenue, and the Aftermarket segment. Geographically, the company generates maximum revenue from the United States and the rest from the United Kingdom, China, Poland, Romania, Brazil, and other regions.